GlassScriptPhysician profile
Charles Ampadu
NPI 1962545269
$7,533.02
in general payments reported to CMS, 2019-2025
54 companies · $1,373 in 2025
The $1,373 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $387 · 2021: $542 · 2022: $1,441 · 2023: $1,583 · 2024: $1,481 · 2025: $1,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,436.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $838.55 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $734.55 | 2019-2025 | Ingrezza |
| Lilly USA, LLC | $650.56 | 2022-2025 | Trulicity, Mounjaro, Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $458.16 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $392.15 | 2019-2024 | |
| Ucb, INC. | $384.11 | 2020-2024 | Briviact, Nayzilam |
| Janssen Pharmaceuticals, INC | $361.85 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $340.93 | 2020-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Lundbeck LLC | $300.07 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $287.68 | 2021-2025 | Farxiga, Lokelma, Airsupra |
| Novo Nordisk INC | $271.83 | 2019-2025 | Wegovy |
| Neurelis, INC. | $195.84 | 2023-2025 | Valtoco |
| Sunovion Pharmaceuticals INC. | $193.79 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $184.09 | 2023-2024 | Aptiom |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.73 | 2019-2022 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $131.02 | 2023-2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $117.14 | 2024-2025 | |
| Alcon Vision LLC | $105.87 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $88.22 | 2023-2025 | Baqsimi |
| Janssen Biotech, INC. | $87.85 | 2022-2023 | Symtuza |
| Boston Scientific Corporation | $77.50 | 2023-2025 | Watchman Access System, Watchman Flx |
| Abbvie INC. | $77.31 | 2021-2025 | |
| Amarin Pharma, INC. | $76.54 | 2019-2022 | |
| Emd Serono, INC. | $74.98 | 2022-2024 | Mavenclad |
| Global Blood Therapeutics, INC. | $73.26 | 2021-2022 | |
| Astellas Pharma US INC | $62.76 | 2023-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $62.52 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $58.26 | 2025 | Cobenfy |
| Verona Pharma, INC. | $52.82 | 2025 | Ohtuvayre |
| Abbott Laboratories | $46.04 | 2022-2023 | Infinity |
| Averitas Pharma INC. | $45.29 | 2024 | Qutenza |
| Biogen, INC. | $41.36 | 2025 | Skyclarys |
| Sk Life Science, INC. | $38.89 | 2020-2022 | |
| Optinose US, INC. | $37.81 | 2024 | |
| Avanir Pharmaceuticals, INC. | $36.94 | 2019 | |
| Paratek Pharmaceuticals, INC. | $35.71 | 2024-2025 | Nuzyra |
| Insulet Corporation | $34.61 | 2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.45 | 2023-2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $30.38 | 2022-2024 | Keveyis |
| Merck Sharp & Dohme LLC | $29.47 | 2022 | |
| Allergan, INC. | $27.21 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $25.16 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.11 | 2025 | Caplyta |
| Ardelyx, INC. | $22.48 | 2024 | Ibsrela |
| Pfizer INC. | $20.27 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $19.17 | 2023 | Inpefa |
| Cmp Pharma, INC. | $19.10 | 2020 | |
| Eisai INC. | $18.34 | 2022 | |
| Tactile Systems Technology INC | $16.55 | 2025 | Flexitouch Plus, Nimbl |
| Indivior INC. | $15.46 | 2023 | Perseris |
| Currax Pharmaceuticals LLC | $13.13 | 2020 | |
| Aytu Biopharma, INC. | $13.04 | 2019 | |
| Dermira, INC. | $12.97 | 2020 | |
| Corium, LLC | $7.14 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Ampadu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.